Immunotherapy Improves the Survival of Stage 4 Non–Small Cell Lung Cancer Patients at the US Population Level: The Real‐World Evidence
This SEER analysis found that immunotherapy improved the survival of Stage 4 NSCLC patients at the population level in the United States. This real-world evidence confirms that immunotherapy has truly revolutionized the management of lung cancer.
Authors
- Rui Zhang (ORCID: https://orcid.org/0000-0002-8655-4017)
- Yuxuan Wei (ORCID: https://orcid.org/0000-0003-0332-6834)
- Zhenming Fu (ORCID: https://orcid.org/0000-0002-2743-9529)
- Shijie Wang (ORCID: https://orcid.org/0000-0002-3135-1343)
- Ruyan Chen (ORCID: https://orcid.org/0000-0003-0018-405X)
- Jianglong Han (ORCID: https://orcid.org/0000-0002-4281-5254)
- Rui-Kang Yin
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- China-Japan Friendship Hospital (CN)
- Wuhan University (CN)
- Zhengzhou University (CN)
- Renmin Hospital of Wuhan University (CN)
Publication Details
- Journal
- The Clinical Respiratory Journal
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1111/crj.70000
- Citations
- 5
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Cancer Institute